American Heart Association

🇺🇸United States
Ownership
-
Established
1924-01-01
Employees
-
Market Cap
-
Website
https://www.heart.org
cbsnews.com
·

FDA approves Apple Watch sleep apnea detection tool

FDA approves Apple Watch sleep apnea detection feature, available on Series 9 and Watch Ultra 2 with watchOS 11, alerting users with consistent sleep interruptions to visit a physician.
news-medical.net
·

Coordinated health teams may help improve outcomes for children with Trisomy 21 and ...

A multidisciplinary team addressing physical, psychological, and developmental needs of children with Down syndrome and congenital heart disease can improve their quality of life and longevity, according to a new American Heart Association statement.
aol.com
·

Representation of Women and People of Color in Clinical Trials is Crucial

Cardiovascular diseases and stroke are leading causes of death worldwide. Researchers emphasize the need for diverse clinical trial participants to advance understanding and treatment. Women with atrial fibrillation face higher stroke risk than men, and cardiovascular disease prevalence is highest among non-Hispanic Blacks. The Librexia program, a phase 3 clinical trial, aims to address these gaps by enrolling diverse populations, including women and people of color.
newsroom.heart.org
·

Coordinated care important for children with Down syndrome and congenital heart disease

Coordinated, multidisciplinary care for children with Down syndrome and congenital heart disease can improve quality of life, addressing physical, psychological, and developmental needs. Common conditions include atrial/ventricular septal defects, pulmonary hypertension, and single ventricle heart disease. Early interventions and a comprehensive 'medical home' are crucial for optimal outcomes.
drugs.com
·

Black Stroke Patients More Likely to Arrive Late at Hospital, Without Prior ER Notification

Black stroke patients arrive at ERs 28 minutes later than white patients, increasing risk of death or disability. EMS is 20% less likely to notify hospitals ahead of Black patients' arrival, affecting treatment time. Delays are also seen in more deprived areas, highlighting systemic issues in EMS care.
springermedizin.de
·

Two-stage screening for obstructive sleep apnea in the primary practice setting

Study evaluates automated scoring of Home Sleep Apnea Testing (HSAT) and a two-stage model for OSA in primary care, using the STOP-BANG questionnaire followed by HSAT with automated scoring. Results show strong correlation between automated and manual HSAT scoring, with the two-stage model demonstrating good diagnostic properties. The study highlights the potential of automated HSAT scoring in primary care, reducing referrals by 15.3% and achieving substantial interrater agreement with manual scoring.
nature.com
·

Why does heart disease affect so many young South Asians?

South Asians, despite lacking common heart disease risk factors, face elevated risks due to genetics and lifestyle factors, prompting research initiatives to understand and address these disparities.
theglobeandmail.com
·

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent ...

Cardiol Therapeutics to present Phase II MAvERIC-Pilot study data on CardiolRx™ for recurrent pericarditis at the American Heart Association Scientific Sessions 2024, showcasing marked reductions in pain and inflammation.
investing.com
·

Cardiol Therapeutics to present Phase II study results

Cardiol Therapeutics to present Phase II MAvERIC-Pilot study data on CardiolRx™ for pericarditis at American Heart Association Scientific Sessions on Nov 18, 2024. The study showed significant symptom reduction at 8 weeks and will support a Phase III trial. The company also received a Buy rating from Roth/MKM with a $10.00 price target and has sufficient cash reserves to fund operations into 2026.
newsfilecorp.com
·

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent

Cardiol Therapeutics completes MAvERIC Phase II study in recurrent pericarditis; results to be presented at American Heart Association Scientific Sessions 2024. The study, led by Dr. S. Allen Luis, demonstrated CardiolRx™'s efficacy in reducing pericarditis pain and inflammation. Full clinical data will be reported in an oral presentation on November 18, 2024.
© Copyright 2024. All Rights Reserved by MedPath